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Abstract
Background: The preferred immunosuppressive drug
for long term treatment of myasthenia gravis (MG) is
azathioprine (AZA). Mycophenolate mofetil (MMF)
was suggested as an effective and safe second line al-
ternative to AZA.
Methods: In a prospective open-label study, 11 patients
with acetylcholine receptor antibody (AChR-ab) posi-
tive MG (n = 4 ocular MG, n = 7 generalized MG)
were treated with MMF which replaced AZA. Reasons
for the change of immunosuppressant therapy were
side effects (n = 9) or unresponsiveness under AZA (n
= 3).
Results: Mean duration of MMF treatment was 16.9
months (6-46 months). During MMF treatment AZA
side effects resolved in 8/9 patients, concomitant ther-
apy could be discontinued in 4 patients and reduced in
5 patients, and 5 patients remitted and 3 remained in
remission. One MMF-refractory patient required add-
on IVIG therapy and another with ocular MG showed
signs of generalization after 20 months of MG treat-
ment. One patient was diagnosed with bronchial carci-
noma after 10 months of MMF treatment.
Conclusion: Due to its favourable spectrum of side ef-
fects compared to AZA MMF might serve as a sec-
ond-line immunosuppressant in those MG patients
who have not tolerated AZA.
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INTRODUCTION
Steroid-sparing immunosupressants such as azathio-
prine (AZA) for the long-term course of myasthenia
gravis (MG) are the preferred first-line treatment for
generalized and severe ocular AChR-ab positive MG.
However, 10-20% of MG patients treated with AZA
do not respond sufficiently to AZA and side effects
occur frequently (nausea, elevated liver enzymes, leu-
co- or thrombocytopenia).
METHODS
In the present prospective open-label study we re-
placed AZA by MMF in eleven patients with AChR-ab
positive MG and analysed the effect and safety of
MMF for a mean duration of 16.9 months ﾱ11.1 (6-
46). Four patients with pure ocular and seven patients
with generalized MG were included. AChR-ab titer,
QMGS, MGFA postintervention status, and concomi-
tant drugs were assessed before the beginning and
during MMF treatment (Table 1).
RESULTS
The reasons for the exchange from AZA to MMF
were gastrointestinal (liver enzyme increase n = 4,
nausea/vomiting n = 2, increase of pancreatic en-
zymes n = 1) and haematological adverse effects (leu-
co- or pancytopenia n = 3), peripheral edema (n = 1),
unresponsiveness to AZA (n = 3). According to the
QMGS treatment resulted in complete (pat. 8) and in-
complete (pat.6, 7, 10, 11) pharmacological remission,
three patients remained in complete pharmacological
remission (pat. 1, 5) or with minimal manifestation
(pat. 2). Clinical improvement was seen after a period
of 2-9 months. In two patients clinical improvement
along with decreasing AChR-ab occurred after more
than six months on MMF (pat. 7, 11). Patient 3 with
disabling unilateral ptosis was refractory despite a
combined therapy of prednisolone, high dose pyrido-
stigmine, and MMF. Symptoms improved during a
concomitant therapy of intravenous immunoglobins.
Patient 4 showed signs of generalization (head lifting
weakness) after 20 months on MMF. Patient 2 with
mild unilateral ptosis discontinued MMF after sixteen
months due to its fear of side effects. Concomitant
medication (prednisolone, pyridostigmine) could be
discontinued in 4 patients (pat. 1, 2, 5, 7) and reduced
in 5 patients (pat. 4, 6, 8, 10, 11). Laboratory parame-
ters which had led to the change from AZA to MMF
normalized in all patients affected (n = 8) except pat.
9. In the latter patient MMF treatment had to be dis-
continued due to persistent increase of pancreatic en-
zymes and recurrent gastrointestinal problems. One
patient was diagnosed with bronchial carcinoma after
10 months of MMF treatment (pat. 5). Thedaily MMF
dosage ranged from 0.5 to 2.5 g and had to be reduced
in three patients due to gastrointestinal problems (pat.
3), and persistent leucopenia (pat. 10).
DICUSSION
Anecdotic reports, uncontrolled open label and retro-
spective studies with MMF had shown clinical im-
provement and steroid dose reduction in patients with
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severe refractory MG [2, 4]. The time to improvement
in that trials was highly variable and ranged from 2
weeks to 12 months [6, 7]. A small double-blind,
placebo-controlled pilot trial of MMF with concomi-
tant prednisolon and/or cyclosporine A medication in
MG showed a significant improvement of MMF com-
pared to placebo [3]. However, two recent random-
ized, double blind, placebo-controlled studies with
larger cohorts failed to show a benefit for MMF in
generalized MG using quantiative MG scores during a
treatment period of 12 and 36 weeks, respectively [5,
6]. It is unclear whether this was due to the short dura-
tion of the follow-up period, the effect of the add-on
steroid therapy, or the insufficient effect of MMF in
MG itself. Consistent with our study side effects of
MMF are often transitory and mild, including mostly
gastrointestinal symptoms as nausea and diarrhoea or
headache [4, 5]. However, severe side effects as an in-
creased risk of lymphoproliferative disorders [7] and
severe skin reactions might also be associated with
MMF therapy. It remains open whether the bronchial
cancer diagnosed in one of our patients was related to
MMF.
The present study shows that MMF led to the re-
duction of concomitant medication and of AZA in-
duced side effects in the majority of patients.
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